Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2017

View Archived Issues

EpiThany, Merck KGaA and Pfizer to evaluate avelumab in combination with EP-101 in breast cancer

Otic Pharma renamed Novus Therapeutics following merger with Tokai Pharmaceuticals

Novel anti-CD30 CAR T-cell therapy enters clinical study for T-cell malignancies

Meissa Vaccines receives NIH grant to support development of rhinovirus vaccine

FDA expands BTD for Rhythm Pharmaceuticals' setmelanotide

Dosing begins in Abide Therapeutics' fMRI study of ABX-1431

Taiwan FDA approves quadrivalent flu vaccine from Adimmune

Synthetic Biologics' SYN-004 earns FDA breakthrough therapy designation

Corium's Corplex Donepezil demonstrates bioequivalence in pilot study

Lexicon Pharmaceuticals reports additional data from phase III inTandem1 study

Lundbeck updates pipeline progress of first quarter 2017

Newron receives milestone payments linked to FDA approval of Xadago

Mitsubishi Tanabe profiles pipeline progress of fourth quarter of fiscal 2016

Asterias reports promising MRI data from SCiStar trial of AST-OPC1 in spinal cord injury

Etripamil demonstrates statistically significant efficacy in NODE-1 trial in PSVT

Eisai offers overview of fourth quarter of fiscal 2016

PACIFIC trial of durvalumab in stage III NSCLC meets PFS primary endpoint

Beijing Konruns Pharmaceutical Technology identifies novel PDE4 inhibitors

INC Research and inVentiv Health set to merge

Norgine to acquire all shares of Merus Labs International

Jiangsu Nhwa, Wuhan Jiayu patent dopamine and serotonin receptor ligands

NG34scFvPD-1 preclinical data show promise for glioblastoma treatment

Mayo Clinic, Arizona State describe novel anticancer compound targeting QSOX1

rAd.DCN.GM induces antitumor effect in a murine colorectal cancer model

Takeda reviews key events of fourth quarter of fiscal 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...